Leukocyte Differential on Hematology Analyzer Compared and Evaluated
|
By LabMedica International staff writers Posted on 21 Jun 2021 |

Image: The Celltac G fully-automatic hematology analyzer with 33 parameters (Photo courtesy of Nihon Kohden)
A complete blood count (CBC), also known as a full blood count (FBC), is a set of medical laboratory tests that provide information about the cells in a person's blood. The CBC indicates the counts of white blood cells, red blood cells and platelets, the concentration of hemoglobin, and the hematocrit (the volume percentage of red blood cells).
Different hematology analyzer models use various principles to measure the complete blood count (CBC) and leukocyte differential for routine tests in clinical laboratories. The accuracy performance of a hematology analyzer is evaluated using the manual differential leukocyte (Manual-Diff) on blood wedge film (Wedge-Diff) as the traditional reference method.
Clinical Laboratorians at the Kindai University Hospital (Osakasayama, Japan) selected for method comparison, 598 clinical samples and 46 healthy volunteer samples. All samples were collected in tubes containing K2-EDTA. The blood collection tubes, blood collection procedure, and mixing procedure were according to described methods. For method comparison between the three analyzers, 388 clinical samples were used. Blood films were stained with May-Giemsa.
The automated hematology analyzer Celltac G (Nihon Kohden, Tokyo, Japan) was designed to improve leukocyte differential performance. The two comparative hematology analyzers (CAAs) used were XN-9000 (Sysmex, Kobe, Japan) and CELL-DYN Sapphire (Abbott Diagnostics, Santa Clara, CA, USA). In manual differential, two kinds of automated slide makers were used: the Sysmex SP-10 for wedge technique and SPINNER-2000 (Lion-Power, Komatsu, Japan) for spinner technique. The immunophenotypic leukocyte differential reference method (FCM-Ref) was selected, and a flow cytometer Navios (Beckman-Coulter, Indianapolis, IN, USA) was used.
The investigators reported that the Celltac G showed sufficient comparability with the CAAs for each leukocyte differential counting value up to 40.87 × 109/L, and sufficient comparability with FCM-Ref for each leukocyte differential percentage at 0.4–78.5. The identification ratio of the FCM-Ref in CD45-positive cells was 99.7% (99.4% to 99.8%). Differences were found between FCM-Ref/Celltac G/XN-9000/Spinner-Diff and Wedge-Diff for monocytes and neutrophils. The appearance ratio of smudge cells on wedge and spinner film was 12.5% and 0.5%.
The authors concluded that the Celltac G hematology analyzer's leukocyte differential showed adequate accuracy compared with two comparative hematology analyzers, reference flow cytometry method, and two manual methods and was considered suitable for clinical use. The study was published on June 12, 2021 in the Journal of Clinical Laboratory Analysis.
Related Links:
Kindai University Hospital
Nihon Kohden
Sysmex
Abbott Diagnostics
Lion-Power
Beckman-Coulter
Different hematology analyzer models use various principles to measure the complete blood count (CBC) and leukocyte differential for routine tests in clinical laboratories. The accuracy performance of a hematology analyzer is evaluated using the manual differential leukocyte (Manual-Diff) on blood wedge film (Wedge-Diff) as the traditional reference method.
Clinical Laboratorians at the Kindai University Hospital (Osakasayama, Japan) selected for method comparison, 598 clinical samples and 46 healthy volunteer samples. All samples were collected in tubes containing K2-EDTA. The blood collection tubes, blood collection procedure, and mixing procedure were according to described methods. For method comparison between the three analyzers, 388 clinical samples were used. Blood films were stained with May-Giemsa.
The automated hematology analyzer Celltac G (Nihon Kohden, Tokyo, Japan) was designed to improve leukocyte differential performance. The two comparative hematology analyzers (CAAs) used were XN-9000 (Sysmex, Kobe, Japan) and CELL-DYN Sapphire (Abbott Diagnostics, Santa Clara, CA, USA). In manual differential, two kinds of automated slide makers were used: the Sysmex SP-10 for wedge technique and SPINNER-2000 (Lion-Power, Komatsu, Japan) for spinner technique. The immunophenotypic leukocyte differential reference method (FCM-Ref) was selected, and a flow cytometer Navios (Beckman-Coulter, Indianapolis, IN, USA) was used.
The investigators reported that the Celltac G showed sufficient comparability with the CAAs for each leukocyte differential counting value up to 40.87 × 109/L, and sufficient comparability with FCM-Ref for each leukocyte differential percentage at 0.4–78.5. The identification ratio of the FCM-Ref in CD45-positive cells was 99.7% (99.4% to 99.8%). Differences were found between FCM-Ref/Celltac G/XN-9000/Spinner-Diff and Wedge-Diff for monocytes and neutrophils. The appearance ratio of smudge cells on wedge and spinner film was 12.5% and 0.5%.
The authors concluded that the Celltac G hematology analyzer's leukocyte differential showed adequate accuracy compared with two comparative hematology analyzers, reference flow cytometry method, and two manual methods and was considered suitable for clinical use. The study was published on June 12, 2021 in the Journal of Clinical Laboratory Analysis.
Related Links:
Kindai University Hospital
Nihon Kohden
Sysmex
Abbott Diagnostics
Lion-Power
Beckman-Coulter
Latest Hematology News
- New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer
- AI Decision Support System Guides Treatment Selection for Complex Blood Cancers
- Blood Test Helps Predict Short-Term Mortality After Severe Heart Attack
- Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
- Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
- Higher Ferritin Threshold May Improve Iron Deficiency Detection in Children
- Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia
- Advanced CBC-Derived Indices Integrated into Hematology Platforms
- Blood Test Enables Early Detection of Multiple Myeloma Relapse
- Single Assay Enables Rapid HLA and ABO Genotyping for Transplant Matching
- Prognostic Biomarker Identified in Diffuse Large B-Cell Lymphoma
- Routine Blood Test Parameters Link Anemia to Cancer Risk and Mortality
- Prognostic Tool Guides Personalized Treatment in Rare Blood Cancer
- New Platelet Function Assay Enables Monitoring of Antiplatelet Therapy
- Open Multi-Omics Platform Identifies Prognostic Subtypes in Blood Cancers
- AI-Powered Digital Workflow Standardizes Bone Marrow Aspirate Morphology
Channels
Clinical Chemistry
view channel
Blood Test Improves Alzheimer’s Diagnosis and Management Across Care Settings
Early and accurate identification of Alzheimer’s disease remains challenging in routine care, particularly outside memory clinics. Confirmation often depends on positron emission tomography (PET) imaging... Read more
New Immunoassay Enables Ultrasensitive Blood-Based Tau Tangle Measurement
Alamar Biosciences (Fremont, CA, USA) has introduced the first commercial immunoassay for enhanced microtubule binding region tau (eMTBR-Tau). The assay is available within the NULISAseq Neuro 220 multiplexed... Read moreMolecular Diagnostics
view channel
Blood Test Achieves Improved Detection of Advanced Precancerous Colorectal Lesions
Colorectal cancer is the second-leading cause of cancer-related death in the United States, yet screening uptake remains suboptimal. More than 50 million eligible adults are not up to date with recommended... Read more
Community-Based Genetic Screening Reaches Rural and Vulnerable Populations
Many adults inherit genetic changes that increase their risk for cancer and cardiovascular disease, yet access to testing often remains concentrated in large medical centers. Reaching rural and socially... Read moreImmunology
view channel
Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19
Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more
Anti-Lipid Antibody Biomarkers May Identify Early Lyme Disease and Persistent Symptoms
Lyme disease is often missed during its earliest and most treatable stage, while current serologic assays cannot distinguish active infection from prior exposure. Nearly half a million Americans are diagnosed... Read more
Emergency Department Opt-Out Testing Program Identifies Undiagnosed HIV
Undiagnosed HIV continues to drive avoidable morbidity and transmission, with many people identified only after substantial immune damage has occurred. In England, about one in 20 people living with HIV... Read more
Immune Biomarkers Could Identify Risk of Chronic Critical Illness on ICU Admission
Severe traumatic injury can trigger immune and organ dysfunction that complicates recovery in the intensive care unit. A subset of patients develop chronic critical illness, defined as dependence on intensive... Read moreMicrobiology
view channel
Bacterial Growth Assay Predicts COVID-19 Severity From Plasma
COVID-19 presents with a wide clinical spectrum, from mild illness to severe, life-threatening disease. Early differentiation between patients likely to remain mild and those at risk of severe progression... Read more
Gut Microbiome Analysis Identifies Frailty-Related Signatures in Older Adults
Frailty in older adults is marked by increased vulnerability to disease, falls, functional decline, and death, yet its biological drivers remain incompletely understood. Because the gut microbiota influences... Read morePathology
view channel
FDA-Approved Companion Diagnostic Detects PTEN Loss in Prostate Cancer
Prostate cancer is the most common cancer among U.S. men, with more than 300,000 new cases and over 36,000 deaths each year. As targeted therapies emerge for biomarker-defined subgroups, laboratories need... Read more
New AI Test Delivers Rapid Breast Cancer Recurrence Predictions
Recurrent breast cancer remains a persistent driver of morbidity and retreatment, and current risk stratification often depends on genomic assays that are costly and slow. Waiting weeks for results can... Read moreTechnology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing
Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Eurobio Scientific Completes Acquisition of CareDx Lab Products Division
Eurobio Scientific has closed the acquisition of CareDx AB in Sweden and its fully owned subsidiaries in the United States and Australia that constitute CareDx’s Lab Products division. The business will... Read more
Blood-Based CRISPR Test for Tuberculosis Gains Regulatory Approval in Colombia
Colombia remains a high-priority setting for tuberculosis, with a growing need for diagnostics that complement existing testing strategies and improve access to earlier diagnosis. Solutions that function... Read more








